Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Inovio Pharma (INO)

Inovio Pharma (INO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Inovio Pharma 660 W. GERMANTOWN PIKE SUITE 110 PLYMOUTH MEETING PA 19462 USA

www.inovio.com Employees: 122 P: 267-440-4200 F: 267-440-4242

Description:

Inovio Pharmaceuticals, Inc., formerly known as Inovio Biomedical Corporation, is engaged in the discovery, development, and delivery of a new generation of vaccines, called DNA vaccines, focused on cancers and infectious diseases. The Company's electroporation DNA delivery technology uses brief, controlled electrical pulses to increase cellular DNA vaccine uptake. Inovio's clinical programs include human papillomavirus (HPV)/cervical cancer (therapeutic), avian influenza (preventative), hepatitis C virus (HCV) and human immunodeficiency virus (HIV) vaccines. It is advancing preclinical research for a universal seasonal/pandemic influenza vaccine. The Company's partners and collaborators include University of Pennsylvania, National Microbiology Laboratory of the Public Health Agency of Canada, NIAID, Merck, ChronTech, University of Southampton, and HIV Vaccines Trial Network. Inovio Pharmaceuticals, Inc. is headquartered in Blue Bell, Pennsylvania.

Key Statistics

Overview:

Market Capitalization, $K 103,617
Enterprise Value, $K 89,307
Shares Outstanding, K 26,100
Annual Sales, $ 830 K
Annual Net Income, $ -135,120 K
Last Quarter Sales, $ 100 K
Last Quarter Net Income, $ -32,240 K
EBIT, $ -117,110 K
EBITDA, $ -105,790 K
60-Month Beta 0.83
% of Insider Shareholders 2.50%
% of Institutional Shareholders 26.79%
Float, K 25,448
% Float 97.50%
Short Volume Ratio 0.66

Growth:

1-Year Return -17.40%
3-Year Return -95.44%
5-Year Return -86.87%
5-Year Revenue Growth -97.28%
5-Year Earnings Growth 55.43%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.89 on 11/14/24
Next Earnings Date N/A
Earnings Per Share ttm -3.58
EPS Growth vs. Prev Qtr 25.21%
EPS Growth vs. Prev Year 17.62%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%
Most Recent Split 1-12 on 01/25/24

INO Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -118.17%
Return-on-Assets % -83.47%
Profit Margin % -16,279.52%
Debt/Equity 0.00
Price/Sales 126.42
Price/Cash Flow N/A
Price/Book 1.42
Book Value/Share 3.73
Interest Coverage -109.75
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar